Figure 1A-D

1/16




Figure 2A-C

2/16





Figure 3A-B

3/16

a Ociperlimab



b Tiragolumab





Figure 4

ID	Note	G0-GN %	G0F-GN %	G0%	G0F%	Man5%	G1%	G1F%	G2%	G2F%	Afucosylation%	Fuco	Afucosylation
A1217-180112A	RS	0.28	0.75	4.2	60.12	0.86	1.32	28.37	0.11	2.89	5.91		
A1217-1	A1217-0uM	0.52	2.76	2.68	63.02	3.13	0.72	23.14	NA	2.53	3.92	91.45	3.92
A1217-2	A1217-0uM-gal+	0.51	2.65	2.83	60.04	3.06	0.88	26.15	NA	2.72	4.22	91.56	4.22
A1217-3	A1217-50uM	7.47	0.49	51.94	7.07	6.93	16.06	3.49	1.4	0.49	**76.87**	11.54	76.87
A1217-4	A1217-50uM-gal+	6.83	0.42	50.78	6.64	6.37	18.15	3.74	1.75	0.65	**77.51**	11.45	77.51
A1217-5	A1217-100uM	7.85	0.25	58.17	2.55	6.4	16.44	1.31	1.28	0.58	**83.74**	4.69	83.74
A1217-6	A1217-100uM-gal+	7.3	0.22	56.58	2.71	6.22	17.9	1.64	1.49	0.72	**83.27**	5.29	83.27
A1217-7	A1217-150uM	6.6	0.35	61.65	2.07	5.03	15.76	1.8	1.05	0.36	**85.06**	4.58	85.06
A1217-8	A1217-150uM-gal+	6.18	0.34	61.84	2.15	4.57	16.3	1.58	1.16	0.39	**85.48**	4.46	85.48
A1217-9	A1217-200uM	6.08	0.45	61.42	2.42	5.08	13.81	2.75	0.96	0.69	**82.27**	6.31	82.27
A1217-10	A1217-200uM-gal+	5.09	0.44	61.54	2.5	4.47	15.3	2.75	1.09	0.75	**83.02**	6.44	83.02

Figure 5A-B

A)



B)




Figure 6A-D



A
FcγRIIIA-V158
MFI
Con.c(ug/ml)
A1217 WT
A1217 DEL
A1217 DE
A1217 MF
B
FcγRIIIA-F158
MFI
Con.c(ug/ml)
A1217 WT
A1217 DEL
A1217 DE
A1217 MF
C
HEK293 FcgRIIIA V158
MFI
Concentration(μg/ml)
A1217
A1217 AF
A1217 DEL
A1217 MI
D
HEK293 FcgRIIIA F158
MFI
Concentration(μg/ml)
A1217
A1217 DEL
A1217 AF
A1217 MI

Figure 7



2000
1500
1000
500
0
MFI
10-4
10-2
100
102
Con.c(ug/ml)
A1217 WT
A1217 DEL
A1217 DE
A1217 MF

Figure 8



Absorbance OD450 (nM)
8
6
4
2
0
10-2
10-1
100
101
102
Ab concentration (μg/ml)
A1217
A1217AF

Figure 9A



8000
6000
4000
2000
0
Luminescence(RLU)
10-4
10-3
10-2
10-1
100
Concentration(μg/ml)
A1217 WT
A1217 DEL
A1217 DE
A1217 AF

Figure 9B



1500
1000
500
0
Luminescence(RLU)
10-4
10-3
10-2
10-1
100
Concentration(μg/ml)
A1217 WT
A1217 DEL
A1217 DE
A1217 AF

Figure 10A-C



A
Treg in CD3+ T cells(%)
Treg in CD3+ T cells(%)
10
5
0
A1217
A1217MF
A1217AF
0 00
0 01
0.10
1.00
10 00
Ab concentrations, μg/ml
B
CD4+ T cells in CD3+T cells(%)
CD4+ in CD3+(%)
100
80
60
40
20
0
A1217
A1217MF
A1217Af
0.00
0.01
0.10
1.00
10.00
Ab concentrations, μg/ml
C
CD8+ T in CD3+ T cells(%)
CD8+ T in CD3+ T cells(%)
25
20
15
10
5
0
A1217
A1217MF
A1217Af
0.00
0.01
0.10
1.00
10.00
Ab concentrations, μg/ml

Figure 11A-B



A
Donor-1
A1217
A1217MF
A1217AF
%CD107a+ in NK
50
40
30
20
10
0
***
**
HIgG 1ug/ml
0.000
0.001
0.010
0.100
1.000
Conc. µg/ml
B
Donor-2
A1217
A1217MF
A1217AF
%CD107a+ in NK
50
40
30
20
10
0
***
**
HIgG 1ug/ml
0.000
0.001
0.010
0.100
1.000
Conc. µg/ml

Figure 12

13/16




Figure 13

14/16




Figure 14

15/16




Figure 15A-C

16/16

